MktsMarkets

MoonLake Immunotherapeutics
NASDAQ: MLTXKey statistics
MLTX News
Stories mentioning MLTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 54,515 | 56,006 | 60,635 | 49,762 | 36,459 | 40,359 | 35,736 | 23,662 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 70,024 | 65,217 | 71,434 | 60,698 | 47,485 | 49,581 | 43,112 | 30,578 |
| Operating Income (Loss) | (70,024) | (65,217) | (71,434) | (60,698) | (47,485) | (49,581) | (43,112) | (30,578) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 622.00 | 248.00 | 115.00 | 95.00 | 153.00 | 41.00 | 92.00 | 79.00 |
| Net Income (Loss) | (69,707) | (62,425) | (69,729) | (55,220) | (39,944) | (45,606) | (35,390) | (24,267) |
| Earnings Per Share (Basic) | (0.98) | (0.97) | (1.10) | (0.87) | (0.63) | (0.73) | (0.56) | (0.39) |
| Earnings Per Share (Diluted) | (0.98) | (0.97) | (1.10) | (0.87) | (0.63) | (0.73) | (0.56) | (0.39) |
| Weighted Average Shares Outstanding (Basic) | 71,274 | 64,464 | 63,370 | 63,283 | 63,234 | 62,870 | 62,897 | 62,875 |
| Weighted Average Shares Outstanding (Diluted) | 71,274 | 64,464 | 63,370 | 63,283 | 63,234 | 62,870 | 62,897 | 62,875 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About MLTX
MoonLake Immunotherapeutics (NASDAQ: MLTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol MLTX. It last traded at $12.62 (Nov 9, 2026, 9:30 AM ET), up 9.4% on the day. That gives MoonLake Immunotherapeutics a market capitalisation of $983.8M.
Over the past 52 weeks MLTX has traded between $9.46 and $23.29.
For the quarter ended Mar 31, 2026 it reported a net loss of $69.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$69.7M |
| Dec 31, 2025 | — | -$62.4M |
| Sep 30, 2025 | — | -$69.7M |
| Jun 30, 2025 | — | -$55.2M |
From MoonLake Immunotherapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…